Beverly Hills Cancer Center | Beverly Hills, CA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Diagnosis of multiple myeloma (IMWG criteria, Rajkumar et al, 2014)
Measurable disease, as defined by at least 1 of the following:
Refractory to at least one IMiD
Refractory to at least one PI
Refractory to at least one anti-CD38 antibody
Relapsed/refractory to last anti-myeloma regimen
Cohort A: has not received prior BCMA-directed therapy
Cohort B: has received prior BCMA-directed therapy (ADC or CAR T cells)
ECOG performance status ≤2
Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1
Not pregnant and willing to use contraception
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
188 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal